NORDITROPIN (somatropin) by Novo Nordisk. Approved for recombinant human growth hormone [epc]. First approved in 2000.
Drug data last refreshed 18h ago · AI intelligence enriched 1w ago
NORDITROPIN (somatropin) is a recombinant human growth hormone indicated for growth hormone deficiency and related endocrine disorders. It is administered via subcutaneous injection and replaces or supplements naturally occurring growth hormone in patients with insufficient production.
Product faces approaching loss of exclusivity with moderate competitive pressure (30/100), indicating transition planning and potential team restructuring or reallocation.
Recombinant Human Growth Hormone
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature
Safety, Pharmacokinetic (PK) Profile and Efficacy of Inpegsomatropin Injection in Adults With Growth Hormone Deficiency
A Study to Learn How Different Injector Pens Affect the Study Medicine Called Genotropin (Somatropin) Delivery and Taken up Into the Blood in Healthy Adults
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
Worked on NORDITROPIN at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Novo Nordisk is hiring 2 roles related to this product
Working on NORDITROPIN offers limited near-term growth but provides deep expertise in endocrinology and biologic development within a mature, stable franchise. Roles emphasize publications, real-world evidence, and clinical science strategy rather than launch or expansion activities.
2 open roles linked to this drug